Camp4 Therapeutics Corp — Form 10-Q
Filed August 13, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
Josh Mandel-Brehm (CEO) and Kelly Gold (CFO) issued standard Sarbanes-Oxley certifications on August 13, 2026 for the Q2 2026 10-Q (quarter ended June 30, 2026). The certifications attest that financial statements fairly present the company's condition, that disclosure controls and internal controls over financial reporting are effective, and that no material weaknesses or fraud involving management were identified. No specific financial data, changes in controls, or business developments are disclosed in these certification exhibits.
Why this rating
Routine SOX certification exhibits; no new material information. Absence of disclosed control deficiencies is modestly positive for a micro-cap.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.